Drug Profile
Research programme: gene-silencing oligonucleotides - Aceragen
Alternative Names: 3GA platform - Aceragen; Gene-silencing oligonucleotides - Aceragen; GSO - Aceragen; Third generation antisense platform - Aceragen; TLR antagonists for B cell lymphomas - Aceragen; TLR anti-sense oligonucleotides - AceragenLatest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen; Leiden University; National Cancer Institute (USA)
- Class Anti-inflammatories; Antineoplastics; Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action Apolipoprotein B inhibitors; Carrier protein modulators; DUX4 protein modulators; Gene silencing; Immunomodulators; MicroRNA inhibitors; PCSK9 protein inhibitors; RNA interference; Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists; Toll-like receptor antagonists; Toll-like receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; B-cell lymphoma; Hypercholesterolaemia; Inflammation; Psoriasis
- Discontinued Facioscapulohumeral muscular dystrophy; Interstitial cystitis; Ischaemia; Lupus nephritis; Uveitis